Industry sessions

Teva Pharmaceuticals Europe B.V. | 4 December | 12:45-13:45 | Plenary hall

Five years of CGRP pathway mAbs: Using emerging insights to map out clinical decision making

Chair: Gisela Terwindt

Lundbeck A/S | 4 December |  13:50 – 14:10 | Headache theatre

Vyepti®: Exploring the potential of intravenous Anti-CGRP therapy in migraine treatment

Speaker: Giorgio Lambru

Pfizer Inc. | 4 December |  14:15–15:15 | Breakout room 1

Raising the Patient Voice in Migraine Treatment

Chair : Elena Ruiz De La Torre
Speakers: Peter Goadsby, Elena Ruiz De La Torre, Deborah Sloan

AbbVie Inc. | 4 December |  15:45 – 16:45 | Plenary hall

Transforming migraine treatment: An interactive journey with atogepant

Chair: Messoud Ashina (University of Copenhagen, Denmark)
Speakers: Jessica Ailani (Georgetown University Hospital, US)
                  Taoufik Alsaadi (American Center of Psychiatry and Neurology, UAE)

During this interactive symposium, the audience will have the opportunity to decide elements of the migraine journey for a hypothetical patient.

• Describe the potential effect of atogepant on migraine through its mechanism of action
• Evaluate patients to determine their suitability for atogepant and discuss how treatment can be appropriately initiated
• Demonstrate awareness of key data from the atogepant clinical programme, including the ELEVATE and long-term safety clinical trials

AbbVie products will be discussed at this meeting. Promotional meeting developed and funded by AbbVie.
ALL-ATP-240015 | Nov 2024
Full Prescribing Information (Ireland, The Netherlands) is available at this meeting and at the AbbVie booth.

AbbVie Inc. | 5 December |  08:00 – 09:00 | Breakout room 1

Early Diagnosis & Intervention in Migraine

Speakers: Patricia Pozo-Rosich, Peter Goadsby

Pfizer Inc. | 5 December |  10:35 – 10:55 | Headache theatre

What does an optimal response to acute treatment look like? Real-world insights with the use of rimegepant

Speaker: Faisal Amin

Teva Pharmaceuticals Europe B.V. | 5 December |  12:00 – 12:30 | Headache theatre

What does an optimal response to acute treatment look like? Real-world insights with the use of rimegepant

Speakers: Hakan Ashina, Roberta Messina

Pfizer Inc. | 5 December |  12:30 – 13:30 | Plenary hall

Migraine Foundations and Frontiers: Balancing Traditional and Innovative Therapies

Chair: Cristina Tassorelli
Speakers: Cristina Tassorelli, Richard B. Lipto, Nirit Lev

AbbVie Inc. | 5 December | 13:30 – 14:00 | AbbVie Booth 

Beyond the Vial: Expert insights into an injection clinic

Speaker: Christina Sundal (Neuroclinic Norway)

During this interactive clinic demonstration, Dr Sundal will share her key strategies and considerations from her injection clinic outlining clinic preparation, clinic room set-up and pre and post-consultation communication with patients.

Promotional meeting developed and funded by AbbVie. AbbVie products will be discussed in this meeting.
Full (Ireland, The Netherlands) Prescribing information will be available at the AbbVie booth.
ALL-BTX-240155 | November 2024

Grünenthal Ltd. | 5 December |  14:15 – 14:35 | Headache theatre

The Continued Role of Nasal Triptans and Strategies in Triptan Failure

Speakers: Gudrun Goßrau

AbbVie inc. | 5 December |  15:05 – 15:25 | Headache theatre

Atogepant in focus: Insights from the Phase 3 clinical trials

Speakers: Christoph Schankin (University of Bern, Switzerland)

This session will explore the key efficacy and safety data from the atogepant Phase 3 clinical trials with Christoph Schankin.

• Understand the different patient populations that were included in the Phase 3 clinical trials with atogepant
• Understand the impact of atogepant on the mean MMDs through primary endpoint data from the ADVANCE, PROGRESS and ELEVATE clinical trials in patients with ≥4 migraine days per month
• Summarise the safety and tolerability profile of atogepant from the ADVANCE, PROGRESS and ELEVATE clinical trials

AbbVie products will be discussed at this meeting. Promotional meeting developed and funded by AbbVie.
ALL-ATP-240015 | Nov 2024
Full Prescribing Information (Ireland, The Netherlands) is available at this meeting and at the AbbVie booth.

Lundbeck A/S | 6 December |  10:35 – 11:55 | Headache theatre

Vyepti®: Exploring the potential of intravenous Anti-CGRP therapy in migraine treatment

Speaker: Giorgio Lambru

Lundbeck A/S | 6 December |  11:00 – 12:00 | Plenary hall

Targeting neuropeptide signalling in migraine: from pathogenesis to prevention and personalised treatment

Chair: Piero Barbanti

Speakers: Astrid Gendolla, Piero Barbanti, Håkan Ashina

AbbVie inc. | 6 December |  14:00 – 14:20 | Headache theatre

Treatment with atogepant: What do our patients want to know?

Speakers: Antonio Russo (University of Campania “Luigi Vanvitelli”, Italy)

This session will explore the burden of migraine through a hypothetical patient-centred lens with Antonio Russo.

• Recognise the burden of migraine from the perspective of a hypothetical patient and the different ways migraine can impact their daily lives.
• Understand the importance of communication between patients being treated with atogepant and clinicians
• Be able to adapt approaches based on the individual needs of a suitable patient with migraine

AbbVie products will be discussed at this meeting. Promotional meeting developed and funded by AbbVie.
ALL-ATP-240015 | Nov 2024
Full Prescribing Information (Ireland, The Netherlands) is available at this meeting and at the AbbVie booth.

Novartis | 6 December |  14:45 – 15:05 | Headache theatre

Anti-CGRPs in Migraine: Benefits of switching from non-specific oral migraine preventives

Speaker: Patricia Pozo-Rosich

Pfizer Inc. | 6 December |  15:20 – 15:40 | Headache theatre

Back on track: Navigating migraine prevention with rimegepant

Speaker: Sait Ashina

Organon Inc. | Plenary Hall | 15:45 – 16:45

The impact of sex hormones on migraine during women’s life journey

Chair: Gisela Terwindt
Speakers: Gisela Terwindt, Britt van der Arend, Margarita Sanchez del Rio, Shazia Afridi

NL-EMG-110011/PP-GZ-NL-0404 November 2024